Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Eccles

Showing results (201-210 of 240) with videos related to

Pageof 24
Sort By:
Molecular Cancer Therapeutics|June 23, 2017
Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic MelanomaJoo Ern Ang, Akos Pal, Yasmin J Asad, et al.
Journal of Medicinal Chemistry|October 10, 2012
Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/Aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemiaVassilios Bavetsias, Simon Crumpler, Chongbo Sun, et al.
Blood Advances|April 14, 2020
Quizartinib-resistant FLT3-ITD acute myeloid leukemia cells are sensitive to the FLT3-Aurora kinase inhibitor CCT241736Andrew S Moore, Amir Faisal, Grace W Y Mak, et al.
Molecular Medicine (Cambridge, Mass.)|February 23, 2012
Flexible targeting of ErbB dimers that drive tumorigenesis by using genetically engineered T cellsDavid M Davies, Julie Foster, Sjoukje J C Van Der Stegen, et al.
ACS Chemical Biology|July 2, 2025
Mediator Kinase Inhibitor Selectivity and Activity in Colorectal CancerMaria J Ortiz-Ruiz, Olajumoke Popoola, Konstantinos Mitsopoulos, et al.
Journal of Medicinal Chemistry|February 20, 2019
Binding to an Unusual Inactive Kinase Conformation by Highly Selective Inhibitors of Inositol-Requiring Enzyme 1α Kinase-EndoribonucleaseGiampiero Colombano, John J Caldwell, Thomas P Matthews, et al.
Molecular Cancer Therapeutics|December 31, 2010
Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930Timothy A Yap, Mike I Walton, Lisa-Jane K Hunter, et al.
Journal of Medicinal Chemistry|June 23, 2010
Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases: lead optimization studies toward the identification of an orally bioavailable preclinical development candidateVassilios Bavetsias, Jonathan M Large, Chongbo Sun, et al.
Molecular Cancer Therapeutics|October 3, 2019
High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast CancersSimon J Anderhub, Grace Wing-Yan Mak, Mark D Gurden, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2017
Noninvasive Imaging of Cycling Hypoxia in Head and Neck Cancer Using Intrinsic Susceptibility MRIRafal Panek, Liam Welsh, Lauren C J Baker, et al.
Pageof 24

Showing results (201-210 of 240) with videos related to

Sort By:
Pageof 24
Molecular Cancer Therapeutics|June 23, 2017
Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic MelanomaJoo Ern Ang, Akos Pal, Yasmin J Asad, et al.
Journal of Medicinal Chemistry|October 10, 2012
Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/Aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemiaVassilios Bavetsias, Simon Crumpler, Chongbo Sun, et al.
Blood Advances|April 14, 2020
Quizartinib-resistant FLT3-ITD acute myeloid leukemia cells are sensitive to the FLT3-Aurora kinase inhibitor CCT241736Andrew S Moore, Amir Faisal, Grace W Y Mak, et al.
Molecular Medicine (Cambridge, Mass.)|February 23, 2012
Flexible targeting of ErbB dimers that drive tumorigenesis by using genetically engineered T cellsDavid M Davies, Julie Foster, Sjoukje J C Van Der Stegen, et al.
ACS Chemical Biology|July 2, 2025
Mediator Kinase Inhibitor Selectivity and Activity in Colorectal CancerMaria J Ortiz-Ruiz, Olajumoke Popoola, Konstantinos Mitsopoulos, et al.
Journal of Medicinal Chemistry|February 20, 2019
Binding to an Unusual Inactive Kinase Conformation by Highly Selective Inhibitors of Inositol-Requiring Enzyme 1α Kinase-EndoribonucleaseGiampiero Colombano, John J Caldwell, Thomas P Matthews, et al.
Molecular Cancer Therapeutics|December 31, 2010
Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930Timothy A Yap, Mike I Walton, Lisa-Jane K Hunter, et al.
Journal of Medicinal Chemistry|June 23, 2010
Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases: lead optimization studies toward the identification of an orally bioavailable preclinical development candidateVassilios Bavetsias, Jonathan M Large, Chongbo Sun, et al.
Molecular Cancer Therapeutics|October 3, 2019
High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast CancersSimon J Anderhub, Grace Wing-Yan Mak, Mark D Gurden, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2017
Noninvasive Imaging of Cycling Hypoxia in Head and Neck Cancer Using Intrinsic Susceptibility MRIRafal Panek, Liam Welsh, Lauren C J Baker, et al.
Pageof 24